WO2016085069A1 - 월라스토나이트, 히드록시아파타이트 및 에커마나이트를 포함하는 고강도 결정화 유리 세라믹 - Google Patents
월라스토나이트, 히드록시아파타이트 및 에커마나이트를 포함하는 고강도 결정화 유리 세라믹 Download PDFInfo
- Publication number
- WO2016085069A1 WO2016085069A1 PCT/KR2015/005284 KR2015005284W WO2016085069A1 WO 2016085069 A1 WO2016085069 A1 WO 2016085069A1 KR 2015005284 W KR2015005284 W KR 2015005284W WO 2016085069 A1 WO2016085069 A1 WO 2016085069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glass ceramic
- strength
- crystallized glass
- present
- hydroxyapatite
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C10/00—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
Definitions
- Lumbar spinal stenosis is a condition in which the spinal or neural tube surrounding the spinal nerve is pressed by bone or ligaments thickened by degenerative changes. These thickened bones or ligaments compress the nerves that pass through the lumbar vertebrae, causing back pain or leg pain.
- Patients who can perform non-surgical treatment preferentially, but spinal stenosis that does not respond to a non-surgical treatment for a certain period of time can be treated only by surgery. However, surgical treatment should be considered in patients with acute or severe symptoms who have many limitations in their daily lives or who have disc disease.
- intervertebral fusion using an intervertebral insert cage and a posterior pedicle screw as a surgical treatment for the above diseases.
- the fusion technique often removes or destroys various elements of the spine, such as spinal lamina and spinous processes, which may result in structural deformation of the spine and instability of each region.
- the fusion surgery completely restricts the movement of the treatment site, so that the movement of the adjacent segments may be increased, thereby accelerating lumbar degeneration.
- Surgical methods for complementing the problem of the fusion surgery is a method of expanding the nerve space pressed by inserting the device during the spinal process between the spine and the spine. This can be used instead of removing the bones of the spine or removing the disc to release the existing pressed nerves.
- the intervertebral spacer is a device inserted in the spinous process between the spine and the spine in order to secure nerve space, and is also referred to as an interspinous spacer. This is a good surgical method for patients who have severe symptoms when they slap back and improve when they lean forward.
- the intervertebral spacer may be made of a material such as metal, ceramic, polymer, or the like.
- the material for the intervertebral spacer may be selected in consideration of strength, durability, biocompatibility, body stability, biotoxicity, processability, disinfection / sterilization stability, and the like. It is also important to have magnetic permeability, radiopacity and appropriate hardness. Metals such as titanium have excellent biocompatibility and high strength, but the modulus of elasticity is too high, which may cause stress shielding effects, and interference with strong magnetic fields such as MRI is difficult to follow after the procedure. On the other hand, polymers such as PEEK have the advantages of high strength, low risk of fracture, and moderate modulus of elasticity.
- the biocompatibility has a disadvantage of significantly lower biocompatibility than metals such as ceramic or titanium such as hydroxyapatite.
- Ceramics, such as hydroxyapatite or bioglass have high biocompatibility, but may be difficult to use alone due to their low strength and high breakdown potential.
- the present inventors have made intensive studies to improve the strength and lower the possibility of fracture so that ceramics, which are highly biocompatible materials, can be used as bone graft materials.
- several ceramics such as CaO-Si 2 OP 2 O 5 -B 2 O 3- MgO is conventionally used in the preparation of crystallized glass ceramic composites (CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 )) obtained by mixing at an appropriate weight ratio and sintering at high temperature.
- the present invention was completed by confirming that the strength can be remarkably improved in comparison with the wollastonite / hydroxyapatite composite glass ceramic or the hydroxyapatite sintered body.
- One object of the present invention is to provide a crystallized glass ceramic comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 ) in an amount of 30 to 40% by weight, respectively.
- Another object of the present invention is a crystallization comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 ) in a weight ratio of 30 to 40:30 to 40:30 to 40 It is to provide a glass ceramic composition.
- Still another object of the present invention is to provide a bone graft material including the glass ceramic.
- Still another object of the present invention is to provide an intervertebral spacer or a bone tissue replacement medical device manufactured from the bone graft material.
- the bone graft material of the present invention is CaSiO 3 such as Wallastonite and Ca 10 (PO 4 ) 6 (OH) 2
- CaSiO 3 such as Wallastonite and Ca 10 (PO 4 ) 6 (OH) 2
- hydroxyapatite (HA) in Ca 2 Mg (Si 2 O 7 ) for example,
- the crystallized glass ceramics which are crystallized by high temperature sintering of the mixed composition further containing Akermanite, have a significantly improved strength compared to conventional wollastonite / hydroxyapatite composite glass ceramics or hydroxyapatite sintered bodies, so that the intervertebral spacer or It can be usefully used as a material for medical devices for bone tissue replacement.
- 1 is a view showing the results of analyzing the crystal component of the composition according to the present invention.
- FIG. 2 is a view showing the strength of the glass ceramic according to the sintering temperature.
- (A) and (B) show images of glass ceramics prepared by sintering at 800 ° C and 900 ° C, respectively.
- FIG 3 is a view showing an XRD analysis result for confirming the crystallization according to the sintering temperature of the glass ceramic according to the present invention.
- FIG. 4 is a view showing the volume, relative density and compressive strength according to the sintering temperature of the glass ceramic according to the present invention.
- FIG. 5 is a view showing the shape of the sintered body according to the sintering temperature of the glass ceramic according to the present invention.
- a first aspect of the present invention provides a crystallized glass ceramic comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 ), each at 30 to 40% by weight.
- a second aspect of the present invention provides a crystallized glass comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 ) in a weight ratio of 30 to 40:30 to 40:30 to 40. It provides a ceramic composition.
- the third aspect of the present invention provides a bone graft material comprising the glass ceramic.
- the fourth aspect of the present invention provides an intervertebral spacer or a medical device for bone tissue replacement, which is manufactured from the bone graft material.
- the present invention relates to a crystallized glass ceramic comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 ) at 30 to 40% by weight, respectively, preferably CaSiO 3 is Wallastonite, Ca 10 (PO 4 ) 6 (OH) 2 may be hydroxyapatite (HA) and Ca 2 Mg (Si 2 O 7 ) may be Akermanite.
- wallastonite of the present invention is a calcium inosilicate mineral represented by the formula of CaSiO 3 , and may include a small amount of iron, magnesium and manganese instead of calcium.
- impurities and limestone or dolostone are present at high temperatures and pressures in the presence of silica-bearing fluids, such as in skarns or contact metamorphic rocks. It can form when faced with.
- Related minerals may include garnets, vesuvianite, diopside, tremolite, epidote, plagioclase feldspar, pyroxene and calcite Can be.
- wollastonite can be produced by the reaction of silica with calcite which releases carbon dioxide:
- Wollastonite can be used in friction products such as ceramics, brakes and clutches, metalmaking, paint fillers and plastics.
- the main producers are China, India, the United States, Mexico and Finland.
- hydroxyapatite of the present invention is a naturally occurring mineral form of calcium apatite, and has a chemical formula of Ca 5 (PO 4 ) 3 (OH), but since the crystal unit cell includes two entities, it is usually Ca 10 (PO 4 ) 6 (OH) 2 It can be represented.
- the hydroxyapatite means a hydroxy monocomponent of the composite apatite group, and OH ⁇ ions may be substituted with fluoride, chloride, carbonate, or the like to form fluoroapatite or chloroapatite. Pure hydroxyapatite powder is white, while naturally occurring apatite may be brown, yellow or green.
- Hydroxyapatite can not only be produced naturally, but also the sol-gel route, also known as wet chemical deposition, biomimetic deposition, and wet chemical precipitation. ) Or by electrodeposition. Hydroxyapatite may be present in teeth and bone tissue in the human body. Thus, it can be used as a filler to replace the cut bone tissue or as a coating to promote the growth of bone tissue into the prosthetic implant.
- the term "ekermanite” of the present invention is a feldspar mineral of the sorosilicate group represented by Ca 2 Mg [Si 2 O 7 ] and includes calcium, magnesium, silicon and oxygen. It can be produced by contact denaturation of siliceous limestone and dolostone, and sanidinite facies rock. Ackermanite has a Mohs hardness of 5 or 6 and can be grey, green, brown or colorless. It can also have white streaks and gloss like glass or resin.
- the present invention is characterized by providing a material having a significantly increased strength compared to glass ceramics including CaSiO 3 and Ca 10 (PO 4 ) 6 (OH) 2 by further including Ca 2 Mg (Si 2 O 7 ). .
- the crystallized glass ceramic of the present invention may be formed by sintering at a temperature of 850 to 1100 °C. If the sintering temperature is lower than 800 °C may be damaged due to rapid crystallization may not be available as a product. On the other hand, sintering at a temperature exceeding 1100 ° C. is undesirable because it not only entails waste of energy due to unnecessary heating, but also may degrade mechanical properties due to excessive crystallization of the glass component.
- CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 and Ca 2 Mg (Si 2 O 7 ) may be included in a weight ratio of 30 to 40:30 to 40:30 to 40 to provide a glass ceramic of improved strength. It provides a crystallized glass ceramic composition.
- the bone graft material of the present invention may include the glass ceramic.
- the glass ceramic may contain CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2, and Ca 2 Mg (Si 2 O 7 ) in an amount of 30 to 40:30 to 40:30 to 40 to improve strength.
- the crystallized glass ceramic composition containing by weight ratio of can be manufactured by high temperature sintering. Preferred sintering temperatures are as described above.
- the improved bone graft material can be used in the manufacture of intervertebral spacers or bone tissue replacement medical devices.
- the medical device for intervertebral spacer or bone tissue replacement is characterized in that it comprises a crystallized glass ceramic according to the present invention in a portion directly bonded to the surrounding bone.
- a spacer made of a glass ceramic material according to the present invention compared to the case of transplanting autogenous bone into the conventional titanium cage, it was confirmed that the bond is shown in a significantly increased area (Table 2). Therefore, in the manufacture of intervertebral spacers or bone tissue replacement medical devices, it is preferable to include the glass ceramics according to the present invention having excellent compatibility with surrounding bone tissues after implantation in the body, in contact with the surrounding bone tissues.
- the intervertebral spacer or bone tissue replacement medical device manufactured from the bone graft material of the present invention may have a compressive strength of 3000 N to 35,000 N or a torsional strength of 0.6 N ⁇ m to 1.5 N ⁇ m.
- it may have a fatigue strength equal to or more than the maximum compressive strength, which does not break even when repeated 5 million cycles at a repetition rate of 5 Hz and a stress ratio of 10. Therefore, the intervertebral spacer or the bone tissue replacement medical device manufactured by the bone graft material of the present invention can be used both as cervical spine spacer or lumbar spine spacer for higher strength.
- the term "compressive strength" of the present invention may mean the maximum stress of a material that can withstand under compressive load.
- the compressive strength of a material broken into fragments during compression can be defined in the agreement as an independent property, but the compressive strength of materials that do not break into compression can be defined as the amount of stress required to distort any amount of material. have.
- the force applied in the test instrument can be measured by plotting it against deformation. In the compression test, the compressive strength can be calculated by dividing the maximum load by the initial cross section of the specimen.
- torsional strength or torsion refers to the ability of the material to withstand torsional loads, the torsional strength is the maximum strength of the material affected by the torsional load, it can hold the material before fracture Maximum torsional stress may be present. It is also called wave step number or shear strength.
- the unit of measurement may be Newton meters (N ⁇ m) or feet-pound force (ft ⁇ lbf).
- fatigue strength refers to the magnitude of the fluctuating stress required to break a fatigue test specimen by applying a predetermined number of repetitive loads, wherein the repeated number of times is referred to as fatigue life. do. Fatigue strength can generally be measured directly from the SN diagram, but is not limited thereto. ASTM defines fatigue strength, S Nf , as the stress value at which N f cycles break.
- an intervertebral spacer or a bone tissue replacement medical device manufactured with a bone graft according to the present invention may be made of a bone graft material that is a compact molded article having a relative density value of 95% or more of theoretical density, but is not limited thereto.
- the bone graft material is manufactured as a compact as described above can provide a higher strength than the bone graft material can be useful as a spinal spacer or a medical device for bone tissue replacement to favor the load.
- SiO 2 , hydroxyapatite, Ca (OH) 2 , MgO, B 2 O 3 , CaF 2, etc. in powder form were boiled at a high temperature of 1400 ° C. or more for 2 hours or more, and then quenched in water to prepare a glass powder raw material.
- Each raw material is 25 to 35% by weight of SiO 2, 25 to 35% by weight of hydroxyapatite, 18 to 22% by weight of Ca (OH) 2 , 4 to 6% by weight of MgO, 4 to 5% by weight of B 2 O 3 , and CaF 2 Mix at a ratio of 4-5% by weight.
- the glass powder prepared above was molded in the same manner as a general ceramic molding production method known in the art, and then crystallized by high temperature sintering.
- the crystalline phase obtained by the final crystallization was a mixture of wollastonite, hydroxyapatite and eckermanite in similar proportions. This was analyzed through an X-ray diffraction pattern and the results are shown in FIG. 1. Specifically, 2 ⁇ , the main line of each material, is in the range of 29.5 to 30.5 ° for wollastonite, 31.5 to 32.5 ° for hydroxyapatite and 30.5 to 31.5 ° for econateite, and the strength ratio is 36 ⁇ 5, respectively. %, 33 ⁇ 5% and 31 ⁇ 5%.
- the optimal sintering temperature may be 1000 ° C. in which the half width of the XRD diffraction line due to the crystal is greatly reduced (FIG. 3).
- the crystallized glass ceramics according to the present invention prepared by sintering at 900 to 1100 °C corresponds to wollastonite, hydroxyapatite and eckermanite, respectively, formed in a similar ratio regardless of temperature Three distinct peaks were shown, indicating that the crystal phase was well formed in the above temperature range. When sintered at temperatures above 1000 ° C., the half width was significantly reduced, indicating better crystallization.
- a glass ceramic is prepared by the method according to the present invention, except that the other conditions are the same, and the sintering is performed at 50 ° C. in the range of 850 to 1100 ° C., respectively.
- the measurements are shown in Table 1 below and plotted together in the graphs.
- the final shape of the glass ceramic sintered body of the hexahedral form produced by sintering at each temperature shown in Figure 5 was taken.
- the glass ceramics produced by sintering at a temperature of 1050 ° C. or more were found to be somewhat convex in appearance. From these results one can find sintering conditions that provide a combination of volume, relative density and compressive strength suitable for their use. For example, for use as a bone graft material, 1000 °C was selected as the sintering temperature, which has a high compressive strength but does not exhibit an external change, that is, no volume expansion was observed.
- Example 3 Measurement of the strength of the bone graft material according to the present invention
- Wollastonite / HA composite which is a conventional glass ceramic material by measuring the strength of the bone graft material comprising a high-strength crystalline glass ceramic containing wollastonite, hydroxyapatite and eckermanite at a predetermined ratio according to the present invention And values for HA, which is a bio-ceramic sintered body.
- Glass powder was prepared by using SiO 2 , hydroxyapatite and Ca (OH) 2 as a raw material, followed by molding and sintering at 1000 ° C., and sintered wollastonite / HA composite glass ceramic and 100% hydroxyapatite at 1200 ° C.
- One HA sinter was used as a comparative example.
- the strengths of the crystalline glass ceramics of the present invention prepared according to Example 1 and the two comparative examples were measured and the results were compared and analyzed in Table 2 below.
- the final sintered body was made of a 1 cm long cube and polished to homogenize the face to minimize the strength measurement error.
- the bone graft material comprising a high-strength crystalline glass ceramic containing wollastonite, hydroxyapatite and eckermanite according to the present invention is a conventional wollastonite / HA composite glass ceramic material
- 20% and 60% increased compressive strength and 40% and 375% increased bending strength, respectively, compared to HA, which is a bio-ceramic sintered body.
- the fracture toughness increased significantly by about two times for both.
- the high-strength crystallized glass ceramic material according to the present invention exhibits a compressive strength of ⁇ 1321 MPa, theoretically the cervical spine and when produced in the size of 2.27 mm 2 and 6.06 mm 2 , respectively
- the crystallized glass ceramic material of the present invention can meet the requirements as lumbar spine spacers for lumbar use and the general spinal spacers have widths, widths and / or heights of several mm to several centimeters. It was confirmed that the strength required as the spacer could be met.
- the spine spacer prepared from the crystallized glass ceramic material according to the present invention has a fatigue strength without breakage even when the added load is the maximum compressive strength even if the spine spacer is repeated at 5 Hz and the stress ratio is 10 or more than 5 million cycles. It was confirmed. Furthermore, the torsional strength of the vertebral spacer was measured to confirm that it had a value of 0.6 N ⁇ m or more.
- the bonding area for the spacer of the crystallized glass ceramic material according to the present invention was statistically significantly higher than the autogenous bone filled in the titanium cage ( p ⁇ 0.001).
- the area of the spacer or autogenous bone associated with the calculated vertebral endplates is compared in Table 3.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Geochemistry & Mineralogy (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
부피 (ml) | 상대 밀도 (%) | 압축 강도 (N) | |
850℃ | 2.8820 | 99.4733 | 16157.95 |
900℃ | 2.8603 | 100.3449 | 21963.62 |
950℃ | 2.8502 | 100.6912 | 28983.78 |
1000℃ | 2.8631 | 99.8791 | 28940.22 |
1050℃ | 3.1315 | 91.4724 | 33016.09 |
1100℃ | 3.8299 | 74.9538 | 21218.79 |
구분 | 압축강도(MPa) | 굽힘강도(MPa) | 파괴인성(MPa·m1/2) |
월라스토나이트/HA 복합 유리 세라믹 | 1103±94 | 180±10 | 1.54±0.07 |
HA 소결체 | 832±35 | 53±1 | 1.51±0.03 |
실시예 1의 결정성 유리 세라믹 | 1321±40 | 253±13 | 3.0±0.17 |
구분 | 상부 추체 종판 | 하부 추체 종판 |
실시예 1 | 86.0 ± 48.0 mm2 | 81.4 ± 48.6 mm2 |
대조군 | 36.4 ± 16.1 mm2 | 39.3 ± 14.7 mm2 |
Claims (10)
- CaSiO3, Ca10(PO4)6(OH)2 및 Ca2Mg(Si2O7)을 각각 30 내지 40 중량%로 포함하는 결정화 유리 세라믹.
- 제1항에 있어서,CaSiO3는 월라스토나이트(Wallastonite), Ca10(PO4)6(OH)2는 히드록시아파타이트(hydroxyapatite; HA) 및 Ca2Mg(Si2O7)은 에커마나이트(Akermanite)인 것인 결정화 유리 세라믹.
- 제1항에 있어서,CaSiO3 및 Ca10(PO4)6(OH)2을 포함하는 유리 세라믹에 비해 Ca2Mg(Si2O7)을 더 포함하여 증가된 강도를 갖는 것인 결정화 유리 세라믹.
- 제1항에 있어서,850 내지 1100℃ 온도에서 소결하여 형성한 것인 결정화 유리 세라믹.
- CaSiO3, Ca10(PO4)6(OH)2 및 Ca2Mg(Si2O7)을 30 내지 40 : 30 내지 40 : 30 내지 40의 중량비로 포함하는 결정화 유리 세라믹 조성물.
- 제1항 내지 제4항 중 어느 한 항에 기재된 유리 세라믹을 포함하는 골이식재.
- 제6항에 기재된 골이식재로 제조된 척추간 스페이서 또는 골조직 대체용 의료기기.
- 제7항에 있어서,주위 뼈와 직접 결합되는 부위에 제1항의 결정화 유리 세라믹을 포함하는 척추간 스페이서 또는 골조직 대체용 의료기기.
- 제7항에 있어서,3,000N 내지 35,000N의 압축강도 또는 0.6 N·m 내지 1.5 N·m의 비틀림강도를 갖는 것인 척추간 스페이서 또는 골조직 대체용 의료기기.
- 제7항에 있어서,상대밀도 값이 이론밀도의 95% 이상인 치밀 성형체인 골이식재로 제조된 것이 특징인 척추간 스페이서 또는 골조직 대체용 의료기기.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017547365A JP6522773B2 (ja) | 2014-11-28 | 2015-05-27 | ウォラストナイト、ヒドロキシアパタイト及びオケルマナイトを含む高強度結晶化ガラスセラミック |
ES15862804T ES2802410T3 (es) | 2014-11-28 | 2015-05-27 | Vitrocerámica cristalizada de alta resistencia que comprende wollastonita, hidroxiapatita y akermanita |
BR112017011315-5A BR112017011315B1 (pt) | 2014-11-28 | 2015-05-27 | Cerâmica de vidro cristalizado, material de enxerto ósseo e espaçador intervertebral ou dispositivo médico para substituição de tecido ósseo |
US15/531,442 US10293081B2 (en) | 2014-11-28 | 2015-05-27 | High-strength crystallized glass ceramic comprising wollastonite, hydroxyapatite and akermanite |
CN201580064027.XA CN107001121B (zh) | 2014-11-28 | 2015-05-27 | 包含硅灰石、羟磷灰石和镁黄长石的高强度结晶玻璃陶瓷 |
EP15862804.0A EP3225598B1 (en) | 2014-11-28 | 2015-05-27 | High-strength crystallized glass ceramic comprising wollastonite, hydroxyapatite and akermanite |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140169052 | 2014-11-28 | ||
KR10-2014-0169052 | 2014-11-28 | ||
KR10-2015-0069925 | 2015-05-19 | ||
KR1020150069925A KR101724592B1 (ko) | 2014-11-28 | 2015-05-19 | 월라스토나이트, 히드록시아파타이트 및 에커마나이트를 포함하는 고강도 결정화 유리 세라믹 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016085069A1 true WO2016085069A1 (ko) | 2016-06-02 |
Family
ID=56074588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/005284 WO2016085069A1 (ko) | 2014-11-28 | 2015-05-27 | 월라스토나이트, 히드록시아파타이트 및 에커마나이트를 포함하는 고강도 결정화 유리 세라믹 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016085069A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106430984A (zh) * | 2016-09-22 | 2017-02-22 | 陕西科技大学 | 一种利用硅灰石制备硅灰石微晶玻璃的方法 |
RU2824130C1 (ru) * | 2023-09-20 | 2024-08-06 | Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) | Способ получения биокомпозита с антибактериальными свойствами |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560666A (en) * | 1983-12-20 | 1985-12-24 | Hoya Corporation | High strength glass-ceramic containing apatite and alkaline earth metal silicate crystals and process for producing the same |
KR940003461B1 (ko) * | 1992-02-11 | 1994-04-22 | 한국유리공업 주식회사 | 고강도 생체재료용 결정화유리 및 그 제조방법 |
US20120058152A1 (en) * | 2009-02-10 | 2012-03-08 | Azurebio, S.L. | Bone regeneration materials based on combinations of monetite and other bioactive calcium and silicon compounds |
-
2015
- 2015-05-27 WO PCT/KR2015/005284 patent/WO2016085069A1/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560666A (en) * | 1983-12-20 | 1985-12-24 | Hoya Corporation | High strength glass-ceramic containing apatite and alkaline earth metal silicate crystals and process for producing the same |
KR940003461B1 (ko) * | 1992-02-11 | 1994-04-22 | 한국유리공업 주식회사 | 고강도 생체재료용 결정화유리 및 그 제조방법 |
US20120058152A1 (en) * | 2009-02-10 | 2012-03-08 | Azurebio, S.L. | Bone regeneration materials based on combinations of monetite and other bioactive calcium and silicon compounds |
Non-Patent Citations (2)
Title |
---|
LIU, DEAN-MO ET AL.: "Formation of a new bioactive glass-ceramic", JOURNAL OF MATERIALS SCIENCE : MATERIALS IN MEDICINE, vol. 5, no. 1, 1994, pages 7 - 10, XP055445902 * |
SINGH, RAJENDRA KUMAR ET AL.: "Bioactivity of ferrimagnetic MgO-CaO-SiO2-P2O5- Fe2O3 glass-ceramics''.", CERAMICS INTERNATIONAL, vol. 36, no. 1, 2010, pages 283 - 290, XP026747632 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106430984A (zh) * | 2016-09-22 | 2017-02-22 | 陕西科技大学 | 一种利用硅灰石制备硅灰石微晶玻璃的方法 |
RU2824130C1 (ru) * | 2023-09-20 | 2024-08-06 | Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) | Способ получения биокомпозита с антибактериальными свойствами |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101724592B1 (ko) | 월라스토나이트, 히드록시아파타이트 및 에커마나이트를 포함하는 고강도 결정화 유리 세라믹 | |
Tomé-Bermejo et al. | Osteoporosis and the management of spinal degenerative disease (I) | |
Jun-Song et al. | Causes of residual back pain at early stage after percutaneous vertebroplasty: a retrospective analysis of 1,316 cases | |
US7981972B2 (en) | Synthetic graft having a glass network | |
Kim et al. | Self-cutting blades and their influence on primary stability of tapered dental implants in a simulated low-density bone model: a laboratory study | |
WO2016085069A1 (ko) | 월라스토나이트, 히드록시아파타이트 및 에커마나이트를 포함하는 고강도 결정화 유리 세라믹 | |
Rouvillain et al. | Clinical, radiological and histological evaluation of biphasic calcium phosphate bioceramic wedges filling medial high tibial valgisation osteotomies | |
Jung et al. | Serious complication of cement augmentation for damaged pilot hole | |
Wattanutchariya et al. | Appropriate forming conditions for hydroxyapatite-bioactive glass compact scaffold | |
Choryłek | Vertebroplasty and kyphoplasty–advantages and disadvantages used bone cement of PMMA | |
Pitjamit et al. | Suitable forming condition of hydroxyapatite and bioactive glass composites for a bone fixation plate using Taguchi experimental design | |
CN1151319C (zh) | 高强度、高模量可控降解速率的聚磷酸钙纤维及其制备方法 | |
Karpiński et al. | Effect of various admixtures on selected mechanical properties of medium viscosity bone cements: Part 1–α/β tricalcium phosphate (TCP) | |
EP2853622B1 (en) | Method of obtention of faceted fluorapatite nanocrystals | |
Dickinson | COMPOSITION–PROPERTY RELATIONSHIPS IN MULTICOMPONENT GERMANIUM–BASED POLYALKENOATE CEMENTS | |
EP4019478A1 (en) | Bioactive crystallized glass ceramic comprising wollastonite, hydroxyapatite and diopside, and use thereof | |
Ko et al. | An Application of Resonance Frequency Analysis for Evaluating Osseointegration of Dental Implants | |
KR101085935B1 (ko) | 수산화인회석을 이용한 골조직 대체용 매식체의 제조방법 | |
Hardman | The treatment of maxillo-facial injuries in Great Britain in 1980 | |
Mousa et al. | Bone‐bonding ability of bioactive bone cement under mechanical stress | |
Jones | Biomechanical and finite element analyses of alternative cements for use in vertebral kyphoplasty | |
Adel Moh’d Fawzi | A Novel Glass Polyalkenoate Cement for Fixation Purposes in the Skeleton | |
Placek | Characterization, Bioactivity and Antioxidant Capactiy of Yttrium and Cerium Doped Glass-ceramics | |
Adel Moh'd Fawzi | A novel glass polyalkenoate cement for fixation purposes in the skeleton/Adel Moh'd Fawzi AR Alhalawani | |
Arif et al. | Microstructure analysis of SiO2–CaO–P2O5–Na2O ceramic and glass-ceramic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15862804 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017547365 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017011315 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2015862804 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112017011315 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170529 |